Abbvie Parkinson’s Disease Grant

Abbvie Parkinson’s Disease Grant

Status: ACTIVE
Funder: Abbvie Foundation
Amount: US $250,000
Last Updated: May 28, 2025

Summary

The Abbvie Parkinson’s Disease Grant aims to enhance the understanding and management of subcutaneous infusion therapies for advanced Parkinson’s disease. As these therapies become more prevalent, it is crucial for Movement Disorder Specialists and General Neurologists to develop confidence in identifying, mitigating, and managing infusion site events. This grant seeks to provide essential education and resources to support safe and effective treatment options for patients experiencing motor fluctuations.

Overview

Abbvie Parkinson’s Disease Grant Background With the emergence of subcutaneous infusion therapies for the management of advanced Parkinson’s disease, there remains limited understanding by Movement Disorder Specialists and General Neurologists about the identification, mitigation and management strategies for infusion site events that occur with therapy. Statement of Need In the U.S., subcutaneous infusions for the management of motor fluctuations in advanced Parkinson’s disease have recently emerged on the market. This modality for treatment is new to Movement Disorder Specialists and General Neurologists. As the use of these therapies increases in the management of motor fluctuations, it will be important to build confidence and education around the prevention/mitigation, identification, and management of infusion site events most commonly observed with these therapies, supporting their safe and effective use.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Application Details

Call for Grant Applications CFG-PD-2025
AbbVie Independent Education (IE)
Therapeutic Area/Disease State Parkinson’s disease
Focus Mitigation and Management of Infusion Site Events
with Subcutaneous Infusions in Parkinson’s Disease
Issue Date: Wednesday, April 30
Due Date/CFG Close Date: Wednesday, June 11
Decision Date and Notification
Once AbbVie has reached a decision about the grant application, a system-generated email
notification will be sent. If the request is approved, the Authorized Signer identified in the
grant application must log into the AbbVie grant management system to review and approve
the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties
prior to the activity start date. Please do not consider any request approved until an email
notification is received from AbbVie stating that the grant request is approved.
Background
With the emergence of subcutaneous infusion therapies for the management of advanced
Parkinson’s disease, there remains limited understanding by Movement Disorder Specialists
and General Neurologists about the identification, mitigation and management strategies for
infusion site events that occur with therapy.
Eligibility Criteria:
Grant applicants must be U.S.-based and registered in AbbVie’s Grant Management System at
grants.abbvie.com with no outstanding reconciliations.
Transparency
AbbVie and the AbbVie grant review and approval process complies with applicable laws,
regulations, recommendations and guidance, including, without limitation: guidance from the
Department of Health & Human Services Office of Inspector General (OIG), Pharmaceutical
Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association
(AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), the Physician
Payments Sunshine Act (commonly known as the “Sunshine Act” or “Open Payments”), and
internal AbbVie policies and procedures.
AbbVie Call for Grant Applications CFG-PD-2025
Page 1

AbbVie, at its sole discretion, may disclose the details of funded independent medical education
activities, including as may be required by federal, state, and/or local laws and regulations. This
disclosure may include, but shall not be limited to, details of the activity and the grant amount.
Terms and Conditions
AbbVie reserves the right to approve or deny any or all grant applications received as a result of
this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not
responsible for any costs associated with this CFG submission.
Submission Directions
1. Please go to grants.abbvie.com and sign in. First-time users should click “Register”
2. In the grant application:
• STEP 1. Select “Submit New Request” to start the submission process.
• STEP 2. Select the “Education Requests” button to continue the submission process.
• STEP 3. Read the Request Submission Instructions and click “Proceed” to enter the
request form.
• STEP 4. Enter Request Information on the General Information Tab.
o In the Activity Sub-Type field, select Independent Medical Education
o Under Therapeutic Area, select Neuroscience – Parkinsons
o In the Program Title field, start the title of the grant request as: CFG-PD-2025
• STEP 5. Continue entering requested information as outlined in the grant application,
including document uploads.
3. If you have questions or require assistance, please contact:
AbbVie Independent Education Department at abbviegrants@abbvie.com.
IMPORTANT: Grant applications submitted in response to this Call for Grants after the due
date will not be reviewed by the AbbVie Independent Education Department and will be
automatically declined. In addition, grant applications must include the required information
outlined in the Submission Directions. Failure to provide this information may result in the
grant application being declined.
Call for Grant Details
Therapeutic Area/Disease state Neuroscience/Parkinson’s Disease
Target Audience Movement Disorder Specialists and General
Neurologists (including Advanced Practice Providers)
Geographic Scope United States
AbbVie Call for Grant Applications CFG-PD-2025
Page 2

Submission Deadline Wednesday, June 11
Anticipated Notification July
Budget $250,000.00
Statement of Need:
In the U.S., subcutaneous infusions for the management of motor fluctuations in advanced
Parkinson’s disease have recently emerged on the market. This modality for treatment is new
to Movement Disorder Specialists and General Neurologists. As the use of these therapies
increases in the management of motor fluctuations, it will be important to build confidence and
education around the prevention/mitigation, identification, and management of infusion site
events most commonly observed with these therapies, supporting their safe and effective use.
AbbVie Call for Grant Applications CFG-PD-2025
Page 3